Found 941 clinical trials
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)
Primary Objective: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) Secondary Objectives: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) at Week 24 To assess the …
- 123 views
- 19 May, 2023
- 5 locations
BIVV020 in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Primary Objectives: Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: To assess the overall efficacy of BIVV020 in prevention or treatment of AMR To characterize the safety and tolerability of BIVV020 …
- 45 views
- 24 May, 2023
- 1 location
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will …
- 15 views
- 17 May, 2023
- 5 locations
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)
Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS]) Study success is defined either on PFS or OS The primary objective is to determine …
- 181 views
- 12 May, 2023
- 5 locations
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma (TIDE-asthma)
This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma. Study details include: The study duration (per participant) will be …
- 33 views
- 19 May, 2023
- 6 locations
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (LEAP2MONO)
This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and <18 …
- 14 views
- 26 May, 2023
- 3 locations
mRNA-1273-P206
Seeking infants 12 weeks to 5 months of age for Covid-19 Vaccination Trial.
- 0 views
- 17 May, 2023
- 1 location
Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults
The study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years
- 0 views
- 25 May, 2023
- 1 location
Influenza
, and quadrivalent influenza modRNA vaccine (qIRV), in participants 65 to 85 years of age. Participants will receive at Vaccination 1 either: 1 of 4 dose levels of mIRV (either A or B Strain), 1 of 4 dose
- 27 views
- 21 Apr, 2022
- 1 location
Response to the HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy
getting ibrutinib or acalabrutinib for it. Design: This study lasts 6 months from the date of first vaccination. Participants may be screened with:
- 67 views
- 09 Apr, 2019
- 1 location